Pfizer deals extend patent life for a top-selling rare disease drug
BioPharma Dive
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
pharminent
April 28, 2026 (Last updated: April 29, 2026)
BioPharma Dive
Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
